MétaCan
Menu
Back to cohort
Record W3022392020 · doi:10.1002/ejhf.1852

Effects of Vericiguat in Heart Failure with Reduced Ejection Fraction: Do not Forget sST2. Letter Regarding the Article ‘Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) Trial’

2020· letter· en· W3022392020 on OpenAlexaff
Alberto Aimo, Vincenzo Castiglione, Carlo Lombardi

Bibliographic record

VenueEuropean Journal of Heart Failure · 2020
Typeletter
Languageen
FieldMedicine
TopicHeart Failure Treatment and Management
Canadian institutionsSurgical Specialties (Canada)
Fundersnot available
KeywordsEjection fractionHeart failureMedicineInternal medicineCardiologyValsartanNatriuretic peptidePopulationBlood pressure

Abstract

fetched live from OpenAlex

We read with interest the paper by Pieske et al.1 describing the baseline characteristics of patients enrolled in the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Despite the quite extensive description of patient characteristics at baseline, no information about heart failure (HF) biomarkers other than natriuretic peptides is available. Specifically, data about high-sensitivity cardiac troponin T (hs-cTnT) and soluble suppression of tumorigenesis-2 (sST2) have not been provided, although these biomarkers yield strong and independent prognostic significance beyond natriuretic peptides for the prediction of all-cause and cardiovascular mortality and HF hospitalization in patients with chronic HF, particularly those with HF and reduced ejection fraction (HFrEF). While hs-cTnT will be analysed in a planned post-hoc analysis of the VICTORIA trial, sST2 apparently will not.2 This attitude of study investigators may be related to the results of the SOCRATES-PRESERVED (Soluble Guanylate Cyclase Stimulator in Heart Failure Patients with Preserved Ejection Fraction) trial, where no change in sST2 levels was observed, although this was in line with the overall trend of other cardiac biomarkers in this study population, including natriuretic peptides.3 Conversely, sST2 was not evaluated in the SOCRATES-REDUCED (Soluble Guanylate Cyclase Stimulator in Heart Failure with Reduced Ejection Fraction) trial, which showed a trend towards decline in natriuretic peptides in patients with HFrEF treated with vericiguat,4 thus anticipating the announced positive results of the VICTORIA trial. Notably, sacubitril/valsartan, another agent modulating the natriuretic peptide system, has been reported to decrease sST2 levels in HFrEF,5 therefore it would be particularly interesting to investigate this biomarker in HFrEF patients treated with vericiguat. Soluble ST2 can be easily dosed on the same samples collected for galectin-3, which will be measured in this study.2 Therefore, study investigators might consider dosing also sST2 in patients enrolled in the VICTORIA trial, both at baseline and during follow-up examination, to gain further insight on the prognostic value of this biomarker, and to check if a relationship exists between sST2 levels and benefit from vericiguat therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.032
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.020
Threshold uncertainty score0.036

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.032
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0010.001
Science and technology studies0.0010.002
Scholarly communication0.0020.004
Open science0.0030.001
Research integrity0.0200.021
Insufficient payload (model declined to judge)0.0050.005

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.248
Teacher spread0.237 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal of Heart FailureSame topicHeart Failure Treatment and ManagementFrench-language works237,207